Study of antibiotics for difficult Gram-negative infections
Part of Infections clinical trials.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an infection caused by a difficult-to-treat Gram-negative bacterium.
- You are being treated with one of the following: ceftazidime/avibactam alone, cefiderocol alone, or either drug combined with fosfomycin.
- You (or your parent/guardian if you are a child) must agree to sign a consent form.
- If you are a healthy volunteer, you must be 18 or older and have no significant health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
This study compares two ways of giving preventive antibiotics to liver transplant patients who carry resistant bacteria. The goal is to see if targeted antibiotics work better than standard ones at preventing infections without causing more side effects.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
Hear when a new Antimicrobial Resistance (AMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.